BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8675574)

  • 1. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan.
    Baudin E; Schlumberger M; Lumbroso J; Travagli JP; Caillou B; Parmentier C
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2541-4. PubMed ID: 8675574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy.
    Valli N; Catargi B; Ronci N; Leccia F; Guyot M; Roger P; Ducassou D; Tabarin A
    Thyroid; 1999 Jun; 9(6):583-9. PubMed ID: 10411121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 99mTc-EDDA/HYNIC-TOC in the diagnosis of differentiated thyroid carcinoma refractory to radioiodine treatment.
    Czepczyński R; Gryczyńska M; Ruchała M
    Nucl Med Rev Cent East Eur; 2016; 19(2):67-73. PubMed ID: 27479883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.
    Baudin E; Lumbroso J; Schlumberger M; Leclere J; Giammarile F; Gardet P; Roche A; Travagli JP; Parmentier C
    J Nucl Med; 1996 Jun; 37(6):912-6. PubMed ID: 8683310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma.
    Tenenbaum F; Lumbroso J; Schlumberger M; Caillou B; Fragu P; Parmentier C
    J Nucl Med; 1995 May; 36(5):807-10. PubMed ID: 7738653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic management of suspected metastatic thyroid carcinoma: clinical value of octreotide scintigraphy in patients with negative high-dose radioiodine scans.
    Giammarile F; Houzard C; Bournaud C; Hafdi Z; Sassolas G; Borson-Chazot F
    Eur J Endocrinol; 2004 Mar; 150(3):277-83. PubMed ID: 15012611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment.
    Bachelot A; Leboulleux S; Baudin E; Hartl DM; Caillou B; Travagli JP; Schlumberger M
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):376-9. PubMed ID: 15730423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indium-111-DTPA-D-Phe-1-octreotide and technetium-99m-(V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma.
    Kurtaran A; Scheuba C; Kaserer K; Schima W; Czerny C; Angelberger P; Niederle B; Virgolini I
    J Nucl Med; 1998 Nov; 39(11):1907-9. PubMed ID: 9829581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptor scintigraphy and magnetic resonance imaging in recurrent medullary thyroid carcinoma: a comparative study.
    Dörr U; Würstlin S; Frank-Raue K; Raue F; Hehrmann R; Iser G; Scholz M; Guhl L; Buhr HJ; Bihl H
    Horm Metab Res Suppl; 1993; 27():48-55. PubMed ID: 8330872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer.
    Haslinghuis LM; Krenning EP; De Herder WW; Reijs AE; Kwekkeboom DJ
    J Endocrinol Invest; 2001 Jun; 24(6):415-22. PubMed ID: 11434665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma.
    Travagli JP; Cailleux AF; Ricard M; Baudin E; Caillou B; Parmentier C; Schlumberger M
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2675-80. PubMed ID: 9709930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical approach in patients with metastatic differentiated thyroid carcinoma and negative 131I whole body scintigraphy: importance of 99mTc MIBI scan combined with high resolution neck ultrasonography.
    Casara D; Rubello D; Saladini G; Mazzarotto R; Sotti G; Tomasella G; Pelizzo MR
    Tumori; 1999; 85(2):122-7. PubMed ID: 10363078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-111 DTPA-octreotide scintigraphy for disease detection in metastatic thyroid cancer: comparison with F-18 FDG positron emission tomography and extensive conventional radiographic imaging.
    Sarlis NJ; Gourgiotis L; Guthrie LC; Galen B; Skarulis MC; Shawker TH; Patronas NJ; Reynolds JC
    Clin Nucl Med; 2003 Mar; 28(3):208-17. PubMed ID: 12592128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy.
    Gao Z; Biersack HJ; Ezziddin S; Logvinski T; An R
    J Cancer Res Clin Oncol; 2004 Nov; 130(11):649-56. PubMed ID: 15300425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The contribution of somatostatin receptor scintigraphy to the diagnosis of recurrent medullary carcinoma of the thyroid.
    Dörr U; Sautter-Bihl ML; Bihl H
    Semin Oncol; 1994 Oct; 21(5 Suppl 13):42-5. PubMed ID: 7992080
    [No Abstract]   [Full Text] [Related]  

  • 16. Scintigraphy with [111In]octreotide and 201Tl in a Hürthle cell thyroid carcinoma without detectable radio-iodine uptake. Report of a case and review of the literature.
    Kostoglou-Athanassiou I; Pappas A; Gogou L; Kaldrymides P
    Horm Res; 2003; 60(4):205-8. PubMed ID: 14530610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
    Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
    Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indium-111-Octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131.
    Stokkel MP; Reigman HI; Verkooijen RB; Smit JW
    J Cancer Res Clin Oncol; 2003 May; 129(5):287-94. PubMed ID: 12750997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.
    Krenning EP; Bakker WH; Kooij PP; Breeman WA; Oei HY; de Jong M; Reubi JC; Visser TJ; Bruns C; Kwekkeboom DJ
    J Nucl Med; 1992 May; 33(5):652-8. PubMed ID: 1349039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indium-111 octreotide scintigraphy for the detection of non-functioning metastases from differentiated thyroid cancer: diagnostic and prognostic value.
    Stokkel MP; Verkooijen RB; Smit JW
    Eur J Nucl Med Mol Imaging; 2004 Jul; 31(7):950-7. PubMed ID: 14991244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.